Covagen AG is a biopharmaceutical company with a specialized focus on crafting next-generation therapies through innovative protein and antibody fusion for enhanced treatment of inflammatory diseases and cancer. The company's unique approach involves creating bispecific FynomAbs by merging its human Fynomer binding proteins with antibodies, resulting in therapeutics with distinctive action mechanisms and improved effectiveness.
The capability to attach Fynomers to multiple sites on an antibody allows Covagen to develop FynomAbs with customized structures for optimal efficacy. Founded in 2007 as a spin-off from ETH Zurich (Swiss Federal Institute of Technology), Covagen has garnered substantial support from prominent investors such as Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.
Their main objective is to explore novel biological pathways for each product candidate, with a particular focus on their leading FynomAb, COVA322, which is being developed specifically for treating inflammatory conditions like rheumatoid arthritis and psoriatic arthritis. In October 2012, Covagen established a strategic research partnership and licensing agreement with Mitsubishi Tanabe / TRL to develop bispecific FynomAbs against targets chosen by Mitsubishi Tanabe / TRL.
The last investment in Covagen AG was a Fr.58.90M Series B investment on 09 December 2013, with participation from Novartis Venture Fund, Ventech Capital, GIMV, Ascent Biomedical Ventures, Baxter Ventures, MP Healthcare Venture Management, Seroba Life Sciences, Andera Partners, Edmond de Rothschild Private Equity.
